HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.

Abstract
The asymptomatic nature of most Chlamydia trachomatis infections and the lack of appropriate effects by current prevention and management call for vaccine development. We evaluated a recombinant subunit vaccine candidate based on the major outer membrane protein variable segments 2 and 4 (MOMP VS2/4). To achieve maximal immunogenicity and ease of production and purification, MOMP VS2/4 was constructed by using highly immunogenic sequences of MOMP only, thereby minimizing the presence of hydrophobic regions, and spacing the immunogenic epitopes with a flexible amino acid sequence. A purification tag was also added. The MOMP VS2/4 was given intranasally, with or without intravaginal boost, with cholera toxin (CT) adjuvant to C57BL/6 mice, which were screened for immunogenicity and protection against a live challenge infection with C. trachomatis serovar D. Bacterial shedding, cell-mediated responses, and antibody responses were monitored. Immunized mice exhibited significantly less bacterial shedding and were better protected against infertility as compared to unimmunized control mice. Immunizations stimulated both systemic and local specific antibody (IgG1, IgG2c, and IgA) responses, and primed T cells that produced interferon-γ and interleukins 13 and 17 upon challenge with recall antigen. Thus, MOMP VS2/4, in combination with CT adjuvant, stimulated Th1, Th2, and Th17 effector cells, and generated protective immunity associated with less pathology. We regard MOMP VS2/4 as a promising candidate for further development into a mucosal chlamydial vaccine.
AuthorsRonza Hadad, Ellen Marks, Irina Kalbina, Karin Schön, Magnus Unemo, Nils Lycke, Åke Strid, Sören Andersson
JournalAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica (APMIS) Vol. 124 Issue 12 Pg. 1078-1086 (Dec 2016) ISSN: 1600-0463 [Electronic] Denmark
PMID27859689 (Publication Type: Journal Article)
Copyright© 2016 APMIS. Published by John Wiley & Sons Ltd.
Chemical References
  • Adjuvants, Immunologic
  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Vaccines
  • Cytokines
  • Epitopes
  • Porins
  • Recombinant Fusion Proteins
  • Vaccines, Subunit
  • Vaccines, Synthetic
  • omp1 protein, Chlamydia trachomatis
  • Cholera Toxin
Topics
  • Adjuvants, Immunologic (administration & dosage)
  • Administration, Intranasal
  • Administration, Intravaginal
  • Animals
  • Antibodies, Bacterial (analysis, blood)
  • Antigens, Bacterial (genetics, immunology)
  • Bacterial Shedding
  • Bacterial Vaccines (administration & dosage, genetics, immunology)
  • Chlamydia trachomatis (immunology)
  • Cholera Toxin (administration & dosage)
  • Cytokines (metabolism)
  • Disease Models, Animal
  • Epitopes (genetics, immunology)
  • Female
  • Infertility (prevention & control)
  • Lymphogranuloma Venereum (prevention & control)
  • Male
  • Mice, Inbred C57BL
  • Porins (genetics, immunology)
  • Recombinant Fusion Proteins (genetics, immunology)
  • T-Lymphocytes (immunology)
  • Treatment Outcome
  • Vaccines, Subunit (administration & dosage, genetics, immunology)
  • Vaccines, Synthetic (administration & dosage, genetics, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: